Nurix Therapeutics, Inc

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, December 9, 2024.

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City.

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November:

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets.

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix's proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in collaboration with Gilead Sciences and also in IND-enabling studies, in two posters at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C.

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain.

Nurix: An Attractive Early-Stage Biotech Play

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 – October 3, 2024, in Boston, MA.

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024.

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments.

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%

Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price.

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?

San Francisco-based Nurix Therapeutics reported robust results in an ongoing treatment against a stubborn form of leukemia.

Biotech Stock Nurix Therapeutics Jumps On Positive Leukemia Treatment Trial

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

News for Nurix Therapeutics, Inc Stock (NRIX)